{"nctId":"NCT00361335","briefTitle":"A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy","startDateStruct":{"date":"2006-09"},"conditions":["Rheumatoid Arthritis"],"count":643,"armGroups":[{"label":"Group I: 2mg/kg Golimumab + MTX","type":"EXPERIMENTAL","interventionNames":["Drug: Golimumab","Drug: Methotrexate"]},{"label":"Group II: 2mg/kg Golimumab only","type":"EXPERIMENTAL","interventionNames":["Drug: Golimumab","Drug: Placebo"]},{"label":"Group III: 4mg/kg Golimumab + MTX","type":"EXPERIMENTAL","interventionNames":["Drug: Golimumab","Drug: Methotrexate"]},{"label":"Group IV: 4mg/kg Golimumab only","type":"EXPERIMENTAL","interventionNames":["Drug: Golimumab","Drug: Placebo"]},{"label":"Group V: IV Placebo + MTX","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Methotrexate","Drug: Placebo"]}],"interventions":[{"name":"Golimumab","otherNames":[]},{"name":"Methotrexate","otherNames":[]},{"name":"Placebo","otherNames":["sham MTX"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- Must have a diagnosis of active rheumatoid arthritis (RA) (according to the revised 1987 criteria of the ARA (American Rheumatism Association) with at least 4 swollen and 4 tender joints for at least 3 months prior to screening - Have been treated with and tolerated methotrexate (MTX) at a dose of at least 15 mg per week for at least 3 months prior to screening - Have been on a stable MTX dose of greater than or equal to 15 mg per week and less than or eual to 25 mg per week for at least 4 weeks prior to screening - If using non steroidal anti-inflammatory agents (such as naproxen) or other pain relievers for RA, must be on a stable dose for at least 2 weeks prior to the first administration of study agent\n\nExclusion Criteria:\n\n\\- Participants having known hypersensitivity (severe allergy) to human immunoglobulin proteins or other components of golimumab - Having known clinically serious adverse reaction to a biologic anti-TNF agent - Have had history of latent or active granulomatous infection, including tuberculosis, histoplasmosis, or coccidioidomycosis, prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With an American College of Rheumatology (ACR) 50 Response at Week 14","description":"An ACR 50 response is defined as a greater than or equal to 50 percentage improvement from baseline in: 1. Swollen joint count (66 joints) and tender joint count (68 joints) 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Patient's assessment of pain (VAS) (0-10 cm) b. Patient's Global Assessment of Disease activity (VAS) (0-10 cm) c. Physician's Global Assessment of Disease Activity (VAS) (0-10 cm) d. Patient's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein (CRP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"27","spread":null},{"groupId":"OG003","value":"25","spread":null},{"groupId":"OG004","value":"17","spread":null},{"groupId":"OG005","value":"55","spread":null},{"groupId":"OG006","value":"41","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an American College of Rheumatology (ACR) 50 Response at Week 24","description":"ACR 50 response is an improvement of greater than or equal to 50 percentage from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain, patient's global assessemnt of disease activity, Physician's global assessment of disease activity (based on a scale of 0=no disease to 10=severe disease), HAQ (20 questions on life activities) and CRP blood test to measure inflammation).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"15","spread":null},{"groupId":"OG004","value":"12","spread":null},{"groupId":"OG005","value":"56","spread":null},{"groupId":"OG006","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With an American College of Rheumatology (ACR) 20 Response at Week 14","description":"ACR 20 response is an improvement of greater than or equal to 20 percentage from baseline in both the tender and swollen joint count and in at least 3 of the 5 assessments (patient's assessment of pain, patient's global assessemnt of disease activity, Physician's global assessment of disease activity \\[based on a scale of 0=no disease to 10=severe disease), HAQ (20 questions on life activities\\] and CRP blood test to measure inflammation).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"51","spread":null},{"groupId":"OG002","value":"66","spread":null},{"groupId":"OG003","value":"62","spread":null},{"groupId":"OG004","value":"36","spread":null},{"groupId":"OG005","value":"137","spread":null},{"groupId":"OG006","value":"113","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Disease Activity Index Score 28 (Using C-reactive Protein)Moderate or Good Response at Week 14","description":"DAS28 using CRP is a measure of tender and swollen joints (28 joints each) and the patient's assessment of disease activity. Values range from 0 (best) to 10 (worst). A score of higher than 5.1 indicates high disease activity, and a score below 3.2 indicates low disease activity. A \"Good\" response is defined as a patient with a DAS28 score of \\<= 3.2 at Week 14 with improvement from Baseline in DAS28 score of \\> 1.2. A \"Moderate\" response is defined as a patient with DAS28 score of \\>3.2-5.1 at Week 14 with improvement from baseline in DAS28 score of \\>1.2 or a DAS28 score of \\<= 5.1 and improvement from baseline in DAS28 score of \\>0.6 to 1.2","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"80","spread":null},{"groupId":"OG002","value":"94","spread":null},{"groupId":"OG003","value":"83","spread":null},{"groupId":"OG004","value":"57","spread":null},{"groupId":"OG005","value":"183","spread":null},{"groupId":"OG006","value":"163","spread":null}]}]}]},{"type":"SECONDARY","title":"Physical Component Summary (PCS) Score of the Short Form-36 (SF-36) at Week 14","description":"The SF-36 consists of 8 multi-item scales: limitations in physical functioning due to health problems, usual role activities due to physical health problems, bodily pain, usual role activities due to personal or emotional problems, social functioning due to physical or mental health problems, general mental health (psychological distress and well-being), vitality and general health perception. The values are 100=best to 0=worst.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.92","spread":"9.175"},{"groupId":"OG001","value":"4.03","spread":"7.462"},{"groupId":"OG002","value":"6.76","spread":"8.252"},{"groupId":"OG003","value":"5.14","spread":"9.674"},{"groupId":"OG004","value":"4.27","spread":"7.216"},{"groupId":"OG005","value":"6.84","spread":"8.702"},{"groupId":"OG006","value":"4.58","spread":"8.644"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":182},"commonTop":["Upper respiratory tract infection","Rheumatoid arthritis","Headache","Bronchitis","Nausea"]}}}